Authors:
de Leeuw, JR
de Graeff, A
Ros, WJG
Blijham, GH
Hordijk, GJ
Winnubst, JAM
Citation: Jr. De Leeuw et al., Prediction of depression 6 months to 3 years after treatment of head and neck cancer, HEAD NECK, 23(10), 2001, pp. 892-898
Authors:
Hupperets, PSGJ
Wils, JAJM
Volovics, L
Schouten, LJ
Fickers, MMF
Bron, HNLM
Jager, JJ
de Jong, JMA
Blijham, GH
Citation: Psgj. Hupperets et al., Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate (MPA) for node-positive cancer patients, update at 12 years follow up, BREAST, 10(1), 2001, pp. 35-37
Authors:
de Graeff, A
de Leeuw, JRJ
Ros, WJG
Hordijk, GJ
Blijham, GH
Winnubst, JAM
Citation: A. De Graeff et al., Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer, EUR J CANC, 37(3), 2001, pp. 332-339
Authors:
De Leeuw, JRJ
De Graeff, A
Ros, WJG
Hordijk, GJ
Blijham, GH
Winnubst, JAM
Citation: Jrj. De Leeuw et al., Negative and positive influences of social support on depression in patients with head and neck cancer: A prospective study, PSYCHO-ONC, 9(1), 2000, pp. 20-28
Authors:
de Leeuw, JRJ
de Graeff, A
Ros, WJG
Blijham, GH
Hordijk, GJ
Winnubst, JAM
Citation: Jrj. De Leeuw et al., Prediction of depressive symptomatology after treatment of head and neck cancer: The influence of pre-treatment physical and depressive symptoms, coping, and social support, HEAD NECK, 22(8), 2000, pp. 799-807
Authors:
de Graeff, A
de Leeuw, JRJ
Ros, WJG
Hordijk, GJ
Blijham, GH
Winnubst, JAM
Citation: A. De Graeff et al., Pretreatment factors predicting quality of life after treatment for head and neck cancer, HEAD NECK, 22(4), 2000, pp. 398-407
Authors:
Verhaar-Langereis, MJ
Bongers, V
de Klerk, JMH
van Dijk, A
Blijham, GH
Zonnenberg, BA
Citation: Mj. Verhaar-langereis et al., Interferon-alpha induced changes in CEA expression in patients with CEA-producing tumours, EUR J NUCL, 27(2), 2000, pp. 209-213
Authors:
Jager, JJ
Jansen, RLH
Arends, JW
Joosten-Achjanie, S
Volovics, L
Schouten, LJ
De Jong, JMA
Meyenfeldt, MFV
Blijham, GH
Citation: Jj. Jager et al., Anti-apoptotic phenotype is associated with decreased locoregional recurrence rate in breast cancer, ANTICANC R, 20(2B), 2000, pp. 1269-1275
Authors:
Lalisang, RI
Voest, EE
Wils, JA
Nortier, JW
Erdkamp, FL
Hillen, HF
Wals, J
Schouten, HC
Blijham, GH
Citation: Ri. Lalisang et al., Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer, BR J CANC, 82(12), 2000, pp. 1914-1919
Authors:
de Graeff, A
de Leeuw, JRJ
Ros, WJG
Hordijk, GJ
Blijham, GH
Winnubst, JAM
Citation: A. De Graeff et al., A prospective study on quality of life of patients with cancer of the oralcavity or oropharynx treated with surgery with or without radiotherapy, ORAL ONCOL, 35(1), 1999, pp. 27-32
Authors:
de Graeff, A
de Leeuw, RJ
Ros, WJG
Hordijk, GJ
Battermann, JJ
Blijham, GH
Winnubst, JAM
Citation: A. De Graeff et al., A prospective study on quality of life of laryngeal cancer patients treated with radiotherapy, HEAD NECK, 21(4), 1999, pp. 291-296
Authors:
Van Cutsem, E
Cunningham, D
Huinink, WWT
Punt, CJA
Alexopoulos, CG
Dirix, L
Symann, M
Blijham, GH
Cholet, P
Fillet, G
Van Groeningen, C
Vannetzel, JM
Levi, F
Panagos, G
Unger, C
Wils, J
Cote, C
Blanc, C
Herait, P
Bleiberg, H
Citation: E. Van Cutsem et al., Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU), EUR J CANC, 35(1), 1999, pp. 54-59
Authors:
Witteveen, PO
Jacobs, HM
van Groenestijn, MAC
Lodder, AC
van Boxtel, AH
Nieuwland, M
Post, MWM
Touw-Otten, FWMM
Blijham, GH
Citation: Po. Witteveen et al., Assessment of the quality of life of patients with advanced and end-stage cancer or serious infections with a symptom-based or an impact-based instrument, SUPP CARE C, 7(2), 1999, pp. 64-70
Authors:
Witteveen, PO
van Groenestijn, MAC
Blijham, GH
Schrijvers, AJP
Citation: Po. Witteveen et al., Use of resources and costs of palliative care with parenteral fluids and analgesics in the home setting for patients with end-stage cancer, ANN ONCOL, 10(2), 1999, pp. 161-165
Authors:
Verhaar, MJ
Damen, CA
Zonnenberg, BA
Blijham, GH
Citation: Mj. Verhaar et al., In vitro upregulation of carcinoembryonic antigen expression by combinations of cytokines, CANCER LETT, 139(1), 1999, pp. 67-73
Citation: Pc. De Jong et Gh. Blijham, New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women, NETH J MED, 55(2), 1999, pp. 50-58
Authors:
Tinnemans, MMFJ
Lenders, MHJH
Ten Velde, GPM
Blijham, GH
Ramaekers, FCS
Schutte, B
Citation: Mmfj. Tinnemans et al., Prognostic value of cytokinetic parameters in lung cancer after in vivo bromodeoxyuridine labelling, ANTICANC R, 19(1A), 1999, pp. 531-534
Authors:
Jager, JJ
Volovics, L
Schouten, LJ
de Jong, JMA
Hupperets, PSGJ
von Meyenfeldt, MF
Schutte, B
Blijham, GH
Citation: Jj. Jager et al., Loco-regional recurrences after mastectomy in breast cancer: prognostic factors and implications for postoperative irradiation, RADIOTH ONC, 50(3), 1999, pp. 267-275
Citation: E. Van Cutsem et Gh. Blijham, Irinotecan versus infusional 5-fluorouracil: A phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil, SEMIN ONCOL, 26(1), 1999, pp. 13-20